Ted Coutilish
(734) 320-7981

(Walnut Creek, CA, October 12, 2013) The National Fragile X Foundation Board of Directors has named Jeffrey Cohen as interim executive director.

“We are fortunate Jeff has accepted this role,” NFXF Board President Brad Whitus said. “As a past board president and current Foundation Director of Government Affairs and Advocacy, he is very knowledgeable, widely respected, trusted and admired within the Fragile X community, and is an outstanding advocate. We are excited to move forward seamlessly under his leadership.”

Cohen succeeds Robby Miller, who joined the NFXF as executive director in 1999.

“We thank Robby for his many years of service, dedication and tireless efforts in leading the Foundation,” Whitus said. “We will continue working closely with Robby over the next few months to ensure a seamless, efficient and effective leadership transition.

“This move is intended to build on recent growth and progress, further increase the Foundation’s visibility, image, reputation and awareness, and raise more dollars to reinvest in new scientific research, discoveries and treatments.”

Whitus said the Foundation will launch a national job search for a permanent replacement to further strengthen key leadership areas, including fundraising, communications, image, management and public policy.

“We believe in, care deeply and support families affected by Fragile X-associated Disorders,” he said. “We are committed to accessibility, advocacy and awareness. We enrich the lives of individuals affected by Fragile X-associated Disorders, their families and the professionals who serve them through support and encouragement, information, research, education, awareness, and advocacy. We are committed to finding a cure for Fragile X-associated Disorders.”

The National Fragile X Foundation, founded in 1984, is a 501(c)(3) nonprofit organization that provides informational, referral and emotional support; educational and awareness materials and activities; support for research including the translation of science into new and improved treatments; and legislative advocacy. More information is available at